Puma Biotechnology (PBYI)
Commercializes NERLYNX for HER2-positive breast cancer and develops alisertib.
Something off on this page? Send us feedback.
Commercializes NERLYNX for HER2-positive breast cancer, with all product revenue tied to that medicine and royalties from ex-U.S. sublicenses. A single reporting segment also carries alisertib, a Takeda-licensed aurora kinase A inhibitor in Phase II oncology studies.
Commercializes NERLYNX, oral neratinib, for certain HER2-positive breast cancers in the United States and receives royalties from partners selling the medicine outside the country. The operating model is narrow: one reporting segment, a field-based commercial footprint, and revenue derived through NERLYNX product sales, licenses, and royalties rather than a broad drug portfolio.
Develops alisertib under a Takeda license while studying additional oncology settings, including small cell lung cancer and hormone receptor-positive metastatic breast cancer. Execution depends on physician adoption in approved NERLYNX uses, partner reach in international markets, FDA-defined labels, and clinical progress for alisertib.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $93.9M · Total debt $4.8M · Total assets $192.7M · Shareholders' equity $138.5M
- Revenue
- $56.5M
- Operating income
- $7.6M
- Net income
- $8.2M
No dividends on record.
| Institutions159 holders · as of Mar 31, 2026 · largest filers plus last quarter's tail | ≈ 73.10% | 37.74M shares | |
| Insiders12 holders · as of Jul 8, 2026 | 21.48% | 11.09M shares | |
| Otherremainder | ≈ 5.42% | 2.80M shares |
51.62M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Alan H. AuerbachInsiderdirector, 10 percent owner, officer: President and CEO | 14.07% | 7.26M | Form 4filed Jul 8, 2026 ↗ |
Acorn Capital Advisors, LLCInstitution | 8.00% | 4.13M | 13Fas of Mar 31, 2026 |
BlackRock, Inc.Institution | 6.97% | 3.60M | 13Fas of Mar 31, 2026 |
Anders HoveInsider | 5.31% | 2.74M | 13Gfiled Sep 1, 2023 ↗ |
Acadian Asset Management LLCInstitution | 3.96% | 2.04M | 13Fas of Mar 31, 2026 |
| See all 25 → | |||
13F — a manager's quarterly holdings · 13D/13G — an ownership statement filed at 5% or more · Form 4 — an insider's transaction report
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jul 6, 2026 | Maximo F. Nougues | officer: Chief Financial Officer | −9,386 | $8.26 |
| Jul 6, 2026 | Douglas M. Hunt | officer: See Remarks | −8,460 | $8.26 |
| Jul 6, 2026 | Alan H. Auerbach | director, 10 percent owner, officer: President and CEO | −44,058 | $8.26 |
| Jun 12, 2026 | Allison Dorval | director | −11,610 | $7.20 |
| Jun 12, 2026 | Jay M. Moyes | director | −22,000 | $7.22 |
